Paris - Delayed Quote EUR

PHAXIAM Therapeutics S.A. (PHXM.PA)

0.6900

+0.0120

+(1.77%)

At close: April 15 at 5:35:16 PM GMT+2

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

LYON, France, March 14, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial infections, announces the launch of a bidding process (appel d’offres) until April 11, 2025.

Business Wire last month

PHXM.PA
+1.77%
PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

LYON, France, March 06, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial infections, announces that, following the Company’s request, the Commercial Court of Lyon decided on March 6, 2025, to open a judicial receivership procedure.

Business Wire last month

PHXM.PA
+1.77%
PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

LYON, France, March 06, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), has requested Euronext to suspend the trading of its stock listed on the Euronext Paris market from the publication of this press release, pending the release of an upcoming press release.

Business Wire last month

PHXM.PA
+1.77%
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

LYON, France, January 31, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial infections, announced today an update on the deployment of its ambitious strategy in the phage therapy market, enabling it to maximize its development potential.

Business Wire 2 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

LYON, France & LISBON, Portugal, January 30, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial infections and Technophage SA ("Technophage"), a Portuguese company specializing in GMP phage development, today announces a strategic collaboration. This strategic partnership aims to provide physicians across Europe with access to a comprehensive GMP

Business Wire 2 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

LYON, France, January 13, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM – FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its financial calendar for 2025.

Business Wire 2 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

LYON, France, January 07, 2025--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces an update on its clinical data from patients treated with the Company’s phages under the compassionate status.

Business Wire 3 months ago

PHXM.PA
+1.77%
PHAXIAM: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 31, 2024

LYON, France, January 06, 2025--Regulatory News: PHAXIAM (Paris:PHXM):

Business Wire 3 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

LYON, France, December 30, 2024--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced the clinical results of the PhagoDAIR I pilot study, demonstrating an excellent phage safety profile and a 74% infection control rate in the Phages arm for patients who received a single intra-articular injection, consistent with clinical data that observed in patients tr

Business Wire 3 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056

GlobeNewswire 4 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

Webinar being held today "Evolving strategic context for phages, Introducing new opportunities" to present PHAXIAM Therapeutics strategyBased on the positive evolution in phages therapy market, PHAXIAM’s development strategy could allow the Company to reach operating profitability and positive free cash flow in 2027 Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe a

GlobeNewswire 4 months ago

PHXM.PA
+1.77%
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scalePHAXIAM phages demonstrated outstanding performance against clinical bacterial strains Lyon (France) – November 18, 2024, at 06:00 p.m. CET – PHAXIAM Ther

GlobeNewswire 4 months ago

PHXM.PA
+1.77%
PHAXIAM Reports Third-Quarter 2024 Financial Information

Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024. "The third quarter of 2024 was marked

GlobeNewswire 4 months ago

PHXM.PA
+1.77%
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 002

GlobeNewswire 5 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureusThe clinical protocol also being submitted to the European health authorities and the MHRA in the UKPatients recruitment scheduled to start in Q1 2025 for clinical data readout expected in Q3 2026 Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments

GlobeNewswire 5 months ago

PHXM.PA
+1.77%
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024

Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 226 9326 226 683May 31, 20246 075 1056 226 9896 226 740July 1, 20249 980 66810

GlobeNewswire 6 months ago

PHXM.PA
+1.77%
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study

A Phase 2 study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM’s anti-S. aureus phages added to the standard treatment by surgery and antibiotics 80 patients to be enrolled in 27 French clinical centersValidation of the study protocol by the ANSM expected in H1 2025 Lyon (France), October 9, 2024 – 06:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471

GlobeNewswire 6 months ago

PHXM.PA
+1.77%
PHAXIAM Provides Business and Financial Update For the First Half of 2024

Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic Joint Infections (PJI) strategic program Clinical readout expected before end of year 2024, including Updated Compassionate real life clinical data and PhagoDAIR pilot studyImminent Filing of Investigational New Drug Application (IND) in US and Clinical Trial Application (CTA) in Europe for GLORI

GlobeNewswire 6 months ago

PHXM.PA
+1.77%
Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024

Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056

GlobeNewswire 9 months ago

PHXM.PA
+1.77%
Results of the Combined General Meeting of 28 June 2024

Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon. The shareholders approved all the resolutions on which the Board of Directors recommended a favo

GlobeNewswire 9 months ago

PHXM.PA
+1.77%

Performance Overview

Return	PHXM.PA	CAC 40 (^FCHI)
YTD	-59.17%	-0.61%
1-Year	-76.49%	-8.82%
3-Year	-94.25%	+11.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PHAXIAM Therapeutics S.A. (PHXM.PA)

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

PHAXIAM: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 31, 2024

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Reports Third-Quarter 2024 Financial Information

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024

PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study

PHAXIAM Provides Business and Financial Update For the First Half of 2024

Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024

Results of the Combined General Meeting of 28 June 2024

Performance Overview